Developer docs
API playgroundTry for free, no card

Search company profiles

Yatiri Bio

Full company profile

uuid0004tiq

Namestring
Yatiri Bio
Legal namestring
Yatiri Bio Inc.
Websiteurl
yatiribio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Yatiri Bio is a San Diego-based biotechnology company founded in 2020 that delivers AI-driven proteomics platforms to the biopharmaceutical industry for oncology drug discovery and patient stratification. Its core technology stack integrates high-resolution mass spectrometry-based proteomics (8,000-11,000 proteins per sample), patient-derived ex vivo cellular models (ProteoModels™), a deep learning architecture, and an interactive data portal (ProteoBrowser™). The flagship product, ProteoCharts™, uses deep neural networks to combine unbiased proteomic profiles with clinical metadata and drug response data from proprietary cellular models to predict patient response and identify resistance pathways. The company's primary therapeutic focus is acute myeloid leukemia (AML), with planned expansion into MDS, ovarian, prostate, breast, and colorectal cancers, supported by a pipeline of 7 peer-reviewed publications and an AML dataset exceeding 200 patient samples, 40 functional ex vivo models, and 5,500+ dose-response curves across 50 compounds.

Yatiri Bio generates revenue primarily through milestone-based co-development and licensing partnerships with biopharmaceutical companies, complemented by discovery proteomics services and non-dilutive grant funding. Notable agreements include a collaboration with Foghorn Therapeutics (clinical and sales milestones valued at over $40 million) and an exclusive global option-to-license agreement with Oscotec for denfivontinib. The company's GTM motion is enterprise field sales targeting pharma business development and clinical development leaders, with co-development deals and CRO-style service agreements as the primary revenue mechanics. Following the November 2025 acquisition of NGeneBioAI, Yatiri Bio operates a CLIA/CAP-certified laboratory facility, enabling development of proprietary Laboratory Developed Tests (LDTs) for clinical trial patient stratification — a higher-margin revenue stream layered on top of the existing services business.

The company is venture-backed (specific investors not disclosed) and operates with 11-50 employees from its San Diego headquarters at 6335 Nancy Ridge Dr. Founders Pilgrim Jackson (Ph.D., ex-Celgene), Mahan Abbasian (ex-BMS/Celgene), Afshin Mahmoudi (ex-Celgene), and Raman Afshar (Ph.D., also VP at AnaSpec) bring deep proteomics and drug discovery experience. The scientific advisory board includes John R. Yates III (SEQUEST inventor), Jill Mesirov (GSEA creator), and Jennifer Van Eyk, providing strong scientific credibility. The company's value proposition — articulated as a 15-20% reduction in development timelines and 5x increase in likelihood of regulatory success versus industry benchmarks — rests on the premise that proteomic data, rather than genomics alone, more accurately captures functional disease biology and predicts therapeutic response.

Short descriptiontext

Yatiri Bio is a San Diego-based biotechnology company that uses AI-driven proteomics and patient-derived cellular models to help biopharmaceutical companies stratify oncology patients and de-risk clinical trials, with a primary focus on AML and expansion into solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
proteomics services, biomarker discovery, patient stratification, drug discovery platform, mass spectrometry analysis
Industry3 codes
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAH
Patient Stratification, Risk Prediction & Prognostic Modeling
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Biomarker Discovery and Proteomics Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharma Partnership Milestone Payments
TypeLicensing Royalties
Description

Yatiri Bio uses a pharma partnership model with payments based on discovery, development, regulatory, and commercial milestones. Collaborations include clinical and sales milestones valued at over $40 million (Foghorn agreement) and option-to-license arrangements (Oscotec denfivontinib agreement).

yatiribio.com
2Non-Dilutive Grant Funding
TypeManaged Services
Description

The company secures non-dilutive funding from prominent organizations including the Gates Foundation (proteomics interoperability project) and CDMRP/US Department of Defense ($110K Phase 1 grant for hypopharyngeal cancer).

globenewswire.com
3Laboratory Developed Tests (LDTs) and Companion Diagnostics
TypeProfessional Services
Description

Leveraging its CLIA/CAP-accredited facility, Yatiri Bio develops proprietary Laboratory Developed Tests (LDTs) that stratify patients for clinical trials, creating a de-risked development pathway and potential companion diagnostic revenue.

yatiribio.com
4Discovery Proteomics Services
TypeProfessional Services
Description

The company offers discovery proteomics services including global proteomics on multiple sample types (cell lines, organoids, tissue, clinical samples), PTM analysis, and interactive data portal access through ProteoBrowser™.

yatiribio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1ProteoCharts
Description

AI-driven proteomic platform that integrates unbiased proteomic profiling with clinical data and functional testing in proprietary patient-derived models to create predictive stratification models for disease landscapes.

yatiribio.com
+3 more records
Core offering1 text field

Yatiri Bio is a biotechnology company that delivers AI-driven proteomics-based biomedical data solutions to the pharmaceutical industry, combining high-resolution mass spectrometry proteomics, deep learning, and patient-derived cellular models to enable biomarker-driven patient stratification for oncology clinical trials. The company's core offerings include its ProteoCharts™ patient stratification platform, ProteoModels™ patient-derived cellular models, ProteoBrowser™ interactive data portal, alongside discovery proteomics and efficacy model services for biopharma partners. It operates a CLIA/CAP-accredited laboratory for developing Laboratory Developed Tests (LDTs) for clinical trial patient selection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% concordance between biomarker-guided predictions and observed clinical outcomes in a blinded retrospective validation study for AML/MDS drug response
+4 more records
Product overview1 text field

Yatiri Bio offers a unified proteomics-driven precision medicine platform centered on ProteoCharts™ (AI-driven patient stratification), ProteoModels™ (patient-derived cellular models), and ProteoBrowser™ (interactive data portal). These core products are complemented by Discovery Proteomics services and Efficacy Models for drug testing. The company integrates mass spectrometry-based proteomics, deep learning, and patient-derived ex vivo systems to accelerate oncology drug discovery and enable precise patient selection. Their AML Platform represents a disease-specific implementation combining all core capabilities for acute myeloid leukemia research.

Product and service7 records
1ProteoCharts™
2ProteoModels™
3ProteoBrowser™
4ProteoPathway™
5Discovery Proteomics
6Efficacy Models
7AML Platform
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-24
Description

Yatiri Bio entered into an exclusive global option to license agreement with Oscotec to develop and commercialize denfivontinib (SKI-G-801), a potent multikinase inhibitor for AML treatment. Yatiri Bio identified a novel FLT3-independent biomarker profile using its ProteoCharts platform to identify patients highly responsive to denfivontinib. The company is developing a proprietary LDT to stratify patients for upcoming clinical trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Yatiri Bio and Foghorn Therapeutics signed a collaboration agreement for the further clinical development of FHD-286 (camibirstat), a novel BAF complex inhibitor for R/R AML and MDS. Yatiri Bio's ProteoCharts platform achieved 100% concordance in a blinded retrospective validation study predicting treatment response from pre-dose peripheral blood samples. The agreement includes clinical and sales milestones valued at over $40 million, with Foghorn supplying material for further clinical development.

3NGeneBioAI, Inc.
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-29
Description

Yatiri Bio acquired NGeneBioAI, a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics. The acquisition transferred all NGeneBioAI assets, proprietary technologies, commercial agreements, and intellectual property to Yatiri Bio, including CLIA- and CAP-certified laboratory infrastructure, enhancing Yatiri Bio's AI-proteomics platform and expanding its capability to develop LDTs.

yatiribio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-15
Description

Yatiri Bio and Ordaōs entered a joint development agreement to create novel therapeutics for high-risk subsets of AML. Yatiri Bio uses its patient proteome data and matched ex vivo models to identify two cell surface therapeutic targets, while Ordaōs uses its Ordaōs Design Engine to create in silico de novo protein candidates for in vitro validation. Target leads will be tested in Yatiri Bio's ProteoModels and jointly developed for IND submission.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Yatiri Bio and Fred Hutch Cancer Center entered a Research Collaboration Agreement using AML patient proteomic data from the Stirewalt lab processed through Yatiri Bio's bioinformatic pipeline. Goals include finding correlations between proteomic data and disease progression, stratifying patient samples into groups correlated with oncology models, uncovering biomarkers and pathways, investigating prognostic capabilities, and discovering novel therapeutic targets in AML.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Yatiri Bio entered a collaboration agreement with SCGOI in ovarian cancer for discovery of novel predictive biomarkers and new targets using global proteomics data generated from fresh and derivatized ovarian cancer samples. Yatiri Bio's technology facilitates matching of molecularly defined patient subsets to tailored cellular model systems.

7Dr. Derek Stirewalt (Fred Hutch)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration agreement in AML with Dr. Derek Stirewalt from Fred Hutch Cancer Center focused on discovery of novel AML prognostic and predictive biomarkers as well as unique therapeutic targets. Dr. Stirewalt leads the Fred Hutch/UW Hematopoietic Diseases Repository, a national toll gate for AML biospecimens.

yatiribio.com
8Professor John R. Yates III (The Scripps Research Institute)
Strategic tierCoreTypeOthers
Description

Professor John Yates joined Yatiri Bio's advisory board. As a pioneer in proteomics and inventor of SEQUEST algorithm and shotgun proteomics technique, his expertise in bioinformatics, methods development, and biological applications has been vital to Yatiri Bio's IP development.

yatiribio.com
9Professor Jill Mesirov (UC San Diego / Broad Institute)
Strategic tierCoreTypeOthers
Description

Professor Jill Mesirov joined Yatiri Bio's advisory board. She supports Yatiri Bio's machine learning efforts to integrate disparate data streams and extract actionable knowledge from proteomics data. She is a senior institute fellow at the Broad Institute and pioneered tools including GenePattern and Gene Set Enrichment Analysis (GSEA).

yatiribio.com
10Professor Jennifer Van Eyk (Cedars-Sinai)
Strategic tierMinorTypeOthers
Description

Professor Jennifer Van Eyk joined Yatiri Bio's advisory board. She is a renowned clinical proteomics scientist serving as Erika Glazer Chair in Women's Heart Health at Cedars-Sinai. She supports Yatiri Bio's proteomics efforts related to clinically relevant biomarker development.

yatiribio.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Seer is a direct peer operating a proprietary proteomics platform (Proteograph) that uses nanoparticle-based enrichment plus mass spectrometry for deep, unbiased protein profiling. Both companies target pharma drug discovery and translational research with AI-augmented proteomics, though Seer is broader across indications while Yatiri is more vertically focused on oncology patient stratification.

TypeEmerging player
Description

Cell Signaling Technology is a leading producer of antibodies and proteomics reagents used widely in pharma research and clinical diagnostics, with growing services in proteomics profiling. It is comparable to Yatiri as a proteomics-focused life sciences organization serving pharma and translational researchers, though CST's primary business is reagents rather than integrated AI services.

TypeBroad incumbent
Description

Thermo Fisher Scientific provides mass spectrometry instruments, proteomics workflows, and CRO services through its PPD division, including pharma biomarker discovery and clinical trial services. It is comparable to Yatiri through its proteomics instrument platform and pharma services, though Thermo Fisher operates across the entire life sciences stack rather than focusing on patient stratification.

TypeBroad incumbent
Description

Bio-Techne offers a broad portfolio of proteomics reagents, assays, and analytical tools used by pharma and academic researchers for biomarker discovery. It is comparable to Yatiri as a life sciences tools company serving proteomics-driven translational research, though Bio-Techne's primary revenue comes from reagent catalog products rather than integrated AI services.

TypeDirect peer
Description

Somalogic operates an aptamer-based proteomics platform (SomaScan) for biomarker discovery and pharma research partnerships. It is comparable to Yatiri as a proteomics platform serving pharma with high-plex protein measurements; Somalogic is more established commercially but applies a different measurement chemistry, and is now part of Standard BioTools.

TypeEmerging player
Description

Quanterix develops ultra-sensitive single-molecule array (Simoa) immunoassay technology for protein biomarker detection in pharma research and clinical applications. It is comparable to Yatiri as a proteomics platform serving pharma for biomarker-driven decision-making, though Quanterix's affinity-based assay chemistry differs from Yatiri's mass spectrometry-based approach.

TypeDirect peer
Description

Olink provides antibody-based proximity extension assay proteomics solutions used widely across pharma biomarker discovery and clinical research. It is comparable to Yatiri as a proteomics platform serving biopharma customers for patient stratification and target discovery, though Olink's affinity-based approach differs from Yatiri's unbiased mass spectrometry pipeline.

TypeBroad incumbent
Description

Evotec is a large contract research organization offering drug discovery and development services across modalities, including proteomics and patient-derived model capabilities. It is comparable to Yatiri as a pharma-facing discovery services provider integrating proteomics and cellular models, though Evotec operates at far greater scale and across a much broader service portfolio.

TypeDirect peer
Description

Nautilus Biotechnology is developing a single-molecule protein analysis platform aimed at deep, reproducible proteomic profiling for pharma research and biomarker discovery. It is comparable to Yatiri as a next-generation proteomics platform targeting pharma drug development workflows, although Nautilus focuses on platform instruments rather than service-based patient stratification.

TypeBroad incumbent
Description

Charles River Laboratories provides preclinical CRO services including proteomics, biomarker discovery, and patient-derived model services for pharma clients. It is comparable to Yatiri through its discovery services and biosample analysis capabilities, though Charles River's offerings span the full preclinical pipeline rather than specializing in AI-driven proteomics stratification.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Yatiri Bio

Biomarker Discovery and Proteomics Servicesyatiribio.com

Yatiri Bio is a San Diego-based biotechnology company that uses AI-driven proteomics and patient-derived cellular models to help biopharmaceutical companies stratify oncology patients and de-risk clinical trials, with a primary focus on AML and expansion into solid tumors.

What Yatiri Bio does

Yatiri Bio is a San Diego-based biotechnology company founded in 2020 that delivers AI-driven proteomics platforms to the biopharmaceutical industry for oncology drug discovery and patient stratification. Its core technology stack integrates high-resolution mass spectrometry-based proteomics (8,000-11,000 proteins per sample), patient-derived ex vivo cellular models (ProteoModels™), a deep learning architecture, and an interactive data portal (ProteoBrowser™). The flagship product, ProteoCharts™, uses deep neural networks to combine unbiased proteomic profiles with clinical metadata and drug response data from proprietary cellular models to predict patient response and identify resistance pathways. The company's primary therapeutic focus is acute myeloid leukemia (AML), with planned expansion into MDS, ovarian, prostate, breast, and colorectal cancers, supported by a pipeline of 7 peer-reviewed publications and an AML dataset exceeding 200 patient samples, 40 functional ex vivo models, and 5,500+ dose-response curves across 50 compounds.

Yatiri Bio generates revenue primarily through milestone-based co-development and licensing partnerships with biopharmaceutical companies, complemented by discovery proteomics services and non-dilutive grant funding. Notable agreements include a collaboration with Foghorn Therapeutics (clinical and sales milestones valued at over $40 million) and an exclusive global option-to-license agreement with Oscotec for denfivontinib. The company's GTM motion is enterprise field sales targeting pharma business development and clinical development leaders, with co-development deals and CRO-style service agreements as the primary revenue mechanics. Following the November 2025 acquisition of NGeneBioAI, Yatiri Bio operates a CLIA/CAP-certified laboratory facility, enabling development of proprietary Laboratory Developed Tests (LDTs) for clinical trial patient stratification — a higher-margin revenue stream layered on top of the existing services business.

The company is venture-backed (specific investors not disclosed) and operates with 11-50 employees from its San Diego headquarters at 6335 Nancy Ridge Dr. Founders Pilgrim Jackson (Ph.D., ex-Celgene), Mahan Abbasian (ex-BMS/Celgene), Afshin Mahmoudi (ex-Celgene), and Raman Afshar (Ph.D., also VP at AnaSpec) bring deep proteomics and drug discovery experience. The scientific advisory board includes John R. Yates III (SEQUEST inventor), Jill Mesirov (GSEA creator), and Jennifer Van Eyk, providing strong scientific credibility. The company's value proposition — articulated as a 15-20% reduction in development timelines and 5x increase in likelihood of regulatory success versus industry benchmarks — rests on the premise that proteomic data, rather than genomics alone, more accurately captures functional disease biology and predicts therapeutic response.

Yatiri Bio firmographics

Firmographics
Name
Yatiri Bio
Legal name
Yatiri Bio Inc.
Website
https://yatiribio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Yatiri Bio is a San Diego-based biotechnology company that uses AI-driven proteomics and patient-derived cellular models to help biopharmaceutical companies stratify oncology patients and de-risk clinical trials, with a primary focus on AML and expansion into solid tumors.
Ownership category
akta.pro rank

Yatiri Bio industry classification

Industry
Product category
Biomarker Discovery and Proteomics Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAH
Patient Stratification, Risk Prediction & Prognostic Modeling

Keywords

  • Proteomics services
  • Biomarker discovery
  • Patient stratification
  • Drug discovery platform
  • Mass spectrometry analysis

Where Yatiri Bio is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Yatiri Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Pharma Partnership Milestone Payments: Yatiri Bio uses a pharma partnership model with payments based on discovery, development, regulatory, and commercial milestones. Collaborations include clinical and sales milestones valued at over $40 million (Foghorn agreement) and option-to-license arrangements (Oscotec denfivontinib agreement).
  2. Non-Dilutive Grant Funding: The company secures non-dilutive funding from prominent organizations including the Gates Foundation (proteomics interoperability project) and CDMRP/US Department of Defense ($110K Phase 1 grant for hypopharyngeal cancer).
  3. Laboratory Developed Tests (LDTs) and Companion Diagnostics: Leveraging its CLIA/CAP-accredited facility, Yatiri Bio develops proprietary Laboratory Developed Tests (LDTs) that stratify patients for clinical trials, creating a de-risked development pathway and potential companion diagnostic revenue.
  4. Discovery Proteomics Services: The company offers discovery proteomics services including global proteomics on multiple sample types (cell lines, organoids, tissue, clinical samples), PTM analysis, and interactive data portal access through ProteoBrowser™.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Yatiri Bio product offering

Product offering

Core offering

Yatiri Bio is a biotechnology company that delivers AI-driven proteomics-based biomedical data solutions to the pharmaceutical industry, combining high-resolution mass spectrometry proteomics, deep learning, and patient-derived cellular models to enable biomarker-driven patient stratification for oncology clinical trials. The company's core offerings include its ProteoCharts™ patient stratification platform, ProteoModels™ patient-derived cellular models, ProteoBrowser™ interactive data portal, alongside discovery proteomics and efficacy model services for biopharma partners. It operates a CLIA/CAP-accredited laboratory for developing Laboratory Developed Tests (LDTs) for clinical trial patient selection.

Product overview

Yatiri Bio offers a unified proteomics-driven precision medicine platform centered on ProteoCharts™ (AI-driven patient stratification), ProteoModels™ (patient-derived cellular models), and ProteoBrowser™ (interactive data portal). These core products are complemented by Discovery Proteomics services and Efficacy Models for drug testing. The company integrates mass spectrometry-based proteomics, deep learning, and patient-derived ex vivo systems to accelerate oncology drug discovery and enable precise patient selection. Their AML Platform represents a disease-specific implementation combining all core capabilities for acute myeloid leukemia research.

Differentiator

Problem solved

Functional benefit

Brands

  • ProteoCharts: AI-driven proteomic platform that integrates unbiased proteomic profiling with clinical data and functional testing in proprietary patient-derived models to create predictive stratification models for disease landscapes.
  • ProteoModels
  • ProteoBrowser
  • ProteoPathway

Products and services

  • ProteoCharts™
  • ProteoModels™
  • ProteoBrowser™
  • ProteoPathway™
  • Discovery Proteomics
  • Efficacy Models
  • AML Platform

Quantifiable outcome

  • 100% concordance between biomarker-guided predictions and observed clinical outcomes in a blinded retrospective validation study for AML/MDS drug response
  • +4 more outcomes

Companies that use Yatiri Bio

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Yatiri Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Yatiri Bio partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Oscotec, Inc.coreOEM/ Whitelabel/ Licensing Partner · 24 March 2026Yatiri Bio entered into an exclusive global option to license agreement with Oscotec to develop and commercialize denfivontinib (SKI-G-801), a potent multikinase inhibitor for AML treatment. Yatiri Bio identified a novel FLT3-independent biomarker profile using its ProteoCharts platform to identify patients highly responsive to denfivontinib. The company is developing a proprietary LDT to stratify patients for upcoming clinical trials.
  • Foghorn TherapeuticscoreStrategic or Co-development Partner · 10 February 2026Yatiri Bio and Foghorn Therapeutics signed a collaboration agreement for the further clinical development of FHD-286 (camibirstat), a novel BAF complex inhibitor for R/R AML and MDS. Yatiri Bio's ProteoCharts platform achieved 100% concordance in a blinded retrospective validation study predicting treatment response from pre-dose peripheral blood samples. The agreement includes clinical and sales milestones valued at over $40 million, with Foghorn supplying material for further clinical development.
  • NGeneBioAI, Inc.coreTechnology or Integration · 29 November 2025Yatiri Bio acquired NGeneBioAI, a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics. The acquisition transferred all NGeneBioAI assets, proprietary technologies, commercial agreements, and intellectual property to Yatiri Bio, including CLIA- and CAP-certified laboratory infrastructure, enhancing Yatiri Bio's AI-proteomics platform and expanding its capability to develop LDTs.
  • OrdaōscoreStrategic or Co-development Partner · 15 December 2022Yatiri Bio and Ordaōs entered a joint development agreement to create novel therapeutics for high-risk subsets of AML. Yatiri Bio uses its patient proteome data and matched ex vivo models to identify two cell surface therapeutic targets, while Ordaōs uses its Ordaōs Design Engine to create in silico de novo protein candidates for in vitro validation. Target leads will be tested in Yatiri Bio's ProteoModels and jointly developed for IND submission.
  • Fred Hutch Cancer Center (FHCC)coreStrategic or Co-development PartnerYatiri Bio and Fred Hutch Cancer Center entered a Research Collaboration Agreement using AML patient proteomic data from the Stirewalt lab processed through Yatiri Bio's bioinformatic pipeline. Goals include finding correlations between proteomic data and disease progression, stratifying patient samples into groups correlated with oncology models, uncovering biomarkers and pathways, investigating prognostic capabilities, and discovering novel therapeutic targets in AML.
  • South Coast Gynecologic Oncology, Inc. (SCGOI)minorStrategic or Co-development PartnerYatiri Bio entered a collaboration agreement with SCGOI in ovarian cancer for discovery of novel predictive biomarkers and new targets using global proteomics data generated from fresh and derivatized ovarian cancer samples. Yatiri Bio's technology facilitates matching of molecularly defined patient subsets to tailored cellular model systems.
  • Dr. Derek Stirewalt (Fred Hutch)coreStrategic or Co-development PartnerResearch collaboration agreement in AML with Dr. Derek Stirewalt from Fred Hutch Cancer Center focused on discovery of novel AML prognostic and predictive biomarkers as well as unique therapeutic targets. Dr. Stirewalt leads the Fred Hutch/UW Hematopoietic Diseases Repository, a national toll gate for AML biospecimens.
  • Professor John R. Yates III (The Scripps Research Institute)coreOthersProfessor John Yates joined Yatiri Bio's advisory board. As a pioneer in proteomics and inventor of SEQUEST algorithm and shotgun proteomics technique, his expertise in bioinformatics, methods development, and biological applications has been vital to Yatiri Bio's IP development.
  • Professor Jill Mesirov (UC San Diego / Broad Institute)coreOthersProfessor Jill Mesirov joined Yatiri Bio's advisory board. She supports Yatiri Bio's machine learning efforts to integrate disparate data streams and extract actionable knowledge from proteomics data. She is a senior institute fellow at the Broad Institute and pioneered tools including GenePattern and Gene Set Enrichment Analysis (GSEA).
  • Professor Jennifer Van Eyk (Cedars-Sinai)minorOthersProfessor Jennifer Van Eyk joined Yatiri Bio's advisory board. She is a renowned clinical proteomics scientist serving as Erika Glazer Chair in Women's Heart Health at Cedars-Sinai. She supports Yatiri Bio's proteomics efforts related to clinically relevant biomarker development.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Yatiri Bio competitors and assessment

Company assessment

Direct peers

  • Seer: Seer is a direct peer operating a proprietary proteomics platform (Proteograph) that uses nanoparticle-based enrichment plus mass spectrometry for deep, unbiased protein profiling. Both companies target pharma drug discovery and translational research with AI-augmented proteomics, though Seer is broader across indications while Yatiri is more vertically focused on oncology patient stratification.
  • Somalogic: Somalogic operates an aptamer-based proteomics platform (SomaScan) for biomarker discovery and pharma research partnerships. It is comparable to Yatiri as a proteomics platform serving pharma with high-plex protein measurements; Somalogic is more established commercially but applies a different measurement chemistry, and is now part of Standard BioTools.
  • Olink: Olink provides antibody-based proximity extension assay proteomics solutions used widely across pharma biomarker discovery and clinical research. It is comparable to Yatiri as a proteomics platform serving biopharma customers for patient stratification and target discovery, though Olink's affinity-based approach differs from Yatiri's unbiased mass spectrometry pipeline.
  • Nautilus Biotechnology: Nautilus Biotechnology is developing a single-molecule protein analysis platform aimed at deep, reproducible proteomic profiling for pharma research and biomarker discovery. It is comparable to Yatiri as a next-generation proteomics platform targeting pharma drug development workflows, although Nautilus focuses on platform instruments rather than service-based patient stratification.

Emerging players

  • Cell Signaling Technology: Cell Signaling Technology is a leading producer of antibodies and proteomics reagents used widely in pharma research and clinical diagnostics, with growing services in proteomics profiling. It is comparable to Yatiri as a proteomics-focused life sciences organization serving pharma and translational researchers, though CST's primary business is reagents rather than integrated AI services.
  • Quanterix: Quanterix develops ultra-sensitive single-molecule array (Simoa) immunoassay technology for protein biomarker detection in pharma research and clinical applications. It is comparable to Yatiri as a proteomics platform serving pharma for biomarker-driven decision-making, though Quanterix's affinity-based assay chemistry differs from Yatiri's mass spectrometry-based approach.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher Scientific provides mass spectrometry instruments, proteomics workflows, and CRO services through its PPD division, including pharma biomarker discovery and clinical trial services. It is comparable to Yatiri through its proteomics instrument platform and pharma services, though Thermo Fisher operates across the entire life sciences stack rather than focusing on patient stratification.
  • Bio-Techne: Bio-Techne offers a broad portfolio of proteomics reagents, assays, and analytical tools used by pharma and academic researchers for biomarker discovery. It is comparable to Yatiri as a life sciences tools company serving proteomics-driven translational research, though Bio-Techne's primary revenue comes from reagent catalog products rather than integrated AI services.
  • Evotec: Evotec is a large contract research organization offering drug discovery and development services across modalities, including proteomics and patient-derived model capabilities. It is comparable to Yatiri as a pharma-facing discovery services provider integrating proteomics and cellular models, though Evotec operates at far greater scale and across a much broader service portfolio.
  • Charles River Laboratories: Charles River Laboratories provides preclinical CRO services including proteomics, biomarker discovery, and patient-derived model services for pharma clients. It is comparable to Yatiri through its discovery services and biosample analysis capabilities, though Charles River's offerings span the full preclinical pipeline rather than specializing in AI-driven proteomics stratification.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Yatiri Bio social profiles

Digital presence

Yatiri Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Yatiri Bio leadership team

Management profile

Number of profiles

Profiles8 records

Yatiri Bio subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Yatiri Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Yatiri Bio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yatiri Bio

What does Yatiri Bio do?

Yatiri Bio is a biotechnology company that delivers AI-driven proteomics-based biomedical data solutions to the pharmaceutical industry, combining high-resolution mass spectrometry proteomics, deep learning, and patient-derived cellular models to enable biomarker-driven patient stratification for oncology clinical trials. The company's core offerings include its ProteoCharts™ patient stratification platform, ProteoModels™ patient-derived cellular models, ProteoBrowser™ interactive data portal, alongside discovery proteomics and efficacy model services for biopharma partners. It operates a CLIA/CAP-accredited laboratory for developing Laboratory Developed Tests (LDTs) for clinical trial patient selection.

Is Yatiri Bio a public or private company?

Yatiri Bio is a private company. It is classified as unknown and is currently operating.

When was Yatiri Bio founded?

Yatiri Bio was founded in 2020. It employs 11 to 50 people.

Where is Yatiri Bio based?

Yatiri Bio is headquartered in San Diego, United States, in the North America region.

How does Yatiri Bio make money?

Four revenue lines are on record. Pharma Partnership Milestone Payments are the primary driver. The others are non-Dilutive Grant Funding, laboratory Developed Tests (LDTs) and Companion Diagnostics and discovery Proteomics Services.

Who are Yatiri Bio's main competitors?

Direct peers on record are Seer, Somalogic, Olink and Nautilus Biotechnology. Emerging players are Cell Signaling Technology and Quanterix. Broad incumbents are Thermo Fisher Scientific, Bio-Techne, Evotec and Charles River Laboratories.

Does Yatiri Bio have an API?

No public API is recorded for Yatiri Bio.

What industry is Yatiri Bio in?

Yatiri Bio's product category is Biomarker Discovery and Proteomics Services. Its primary akta.pro industry code is HLAGANAB, Proteomics & Mass Spectrometry Services, with a secondary code of HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterYatiri Bio gains exclusive option to in-license Oscotec’s denfivontinib in AMLYatiri Bio entered an exclusive global option to license Oscotec's denfivontinib (SKI-G-801) for AML treatment. The agreement gives Yatiri exclusive rights to develop and commercialize the multikinase inhibitor, with no financial terms disclosed.Financial PostYatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn's FHD-286Yatiri Bio achieved 100% concordance in a blinded retrospective validation study using Foghorn Therapeutics’ FHD-286 (camibirstat) to predict treatment response in patients with relapsed or refractory acute myeloid leukemia (R/R AML) or myelodysplastic syndrome (MDS), correctly identifying responders and non-responders from pre-dose peripheral blood samples alone. The two companies have signed a collaboration agreement including clinical and sales milestones valued at over $40 million to further develop FHD-286, with Yatiri Bio’s proteomic platform (ProteoCharts™) potentially enabling more precise patient stratification in future clinical trials.GlobeNewswireYatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn’s FHD-286Yatiri Bio reported 100% concordance between its ProteoCharts biomarker predictions and clinical responses to Foghorn's FHD-286 in a blinded retrospective study of R/R AML and MDS patients. The company signed a collaboration with Foghorn for further development, including clinical and sales milestones valued at over $40M.GlobeNewswireYatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn’s FHD-286Yatiri Bio announced results from a blinded retrospective clinical validation study evaluating Foghorn Therapeutics' drug candidate FHD-286 (camibirstat) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome, demonstrating 100% concordance between biomarker-guided predictions and observed clinical outcomes. Following the positive results, Yatiri Bio and Foghorn Therapeutics have signed a collaboration agreement for further clinical development of FHD-286, with clinical and sales milestones valued at over $40 million. The study used Yatiri Bio's AI-driven ProteoCharts platform to correctly identify patients who achieved complete or partial responses versus those with stable disease or treatment failure, using only pre-dose peripheral blood samples.GlobeNewswireYatiri Bio Receives Grant to Advance Proteomics Interoperability in Cancer ResearchYatiri Bio Inc. announced it has received a grant from the Gates Foundation to launch a one-year Proteomics Interoperability project focused on HPV-related cervical cancer research. The project will develop machine learning models to integrate data from three proteomics approaches—unbiased proteomics, aptamer-based proteomics (Somalogic), and antibody-based proteomics (Olink)—into a unified framework for drug discovery and early detection. The company aims to create a scalable model for applying proteomics at scale that can be shared with the scientific community.MoomooYatiri Bio: Received Grant From Gates FoundatYatiri Bio has received a grant from the Gates Foundation to launch a one-year project focused on proteomics interoperability in cancer research. The announcement was made on September 22, 2025, though the article provides limited details about the grant amount or project scope. This represents a non-dilutive funding award from a prominent global health philanthropy organization.SdbnYatiri Bio Acquires NGeneBioAI to Expand AI-Powered Proteomics Platform and Advance Precision Biomarker Discovery – San Diego Biotechnology NetworkYatiri Bio acquired NGeneBioAI, a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics. The acquisition strengthens Yatiri Bio's position in biomarker discovery and translational drug development.Labiotech.euOrdaōs and Yatiri Bio to tackle AMLOrdaōs and Yatiri Bio announced a joint development agreement to create new therapeutics for acute myeloid leukemia (AML) targets. Yatiri Bio will identify two cell surface targets using patient proteomics, while Ordaōs will design mini-protein candidates and validate them in vitro. The partners plan to jointly develop leads for an IND submission.PR NewswireOrdaōs Announces a Joint Development Agreement to Create Novel Therapeutics for AMLOrdaōs, a biotechnology company specializing in mini-protein drug design, announced a joint development agreement with Yatiri Bio to create novel therapeutics targeting two cell surface proteins in Acute Myeloid Leukemia. Yatiri Bio will leverage its patient proteomics database and ex-vivo model systems to identify therapeutic targets, while Ordaōs will use its Design Engine to generate and validate protein candidates in vitro. The companies plan to jointly advance candidates toward an Investigational New Drug application, addressing what the Leukemia & Lymphoma Society describes as one of the most lethal blood cancers, responsible for over 10,000 U.S. deaths annually.